Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
These data suggest that older adults in rural communities may be underdiagnosed with ADRD, and/or diagnosed at later stages of dementia.
Why it matters
This study found that risk-adjusted diagnostic incidence of Alzheimer's disease and related dementias was higher in rural than in metropolitan counties despite lower prevalence, and that metropolitan residents with a diagnosis survived longer. The authors suggest that older adults in rural communities may be underdiagnosed or diagnosed at later stages, but the study does not test any treatment, cure, or prevention.
-
This study aimed to use peripheral plasma d-glutamate levels to differentiate patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) from healthy individuals and to evaluate its prediction ability using machine learning.
Why it matters
In 31 healthy controls, 21 patients with mild cognitive impairment and 133 patients with Alzheimer's disease, plasma d-glutamate levels were lower in the MCI and AD groups, and machine learning models distinguished them from controls with area under the curve of 0.8207 and 0.7900. This suggests d-glutamate may help identify these conditions, but it does not test any treatment, cure or prevention.
-
Recent trials of repetitive transcranial magnetic stimulation (rTMS) have reported encouraging results for improving or stabilizing cognition in patients diagnosed with Alzheimer dementia.
Why it matters
This is a protocol for a double-blind, randomized, placebo-controlled trial of repetitive transcranial magnetic stimulation (rTMS) at two doses versus sham in patients with Alzheimer's disease. No results are reported yet; the authors note that previous rTMS results are inconclusive because of small samples and lack of well-controlled double-blind designs.
-
47/100
Among non-dually eligible beneficiaries, 9.0% (95% confidence interval [CI]: 8.0, 9.1) with ADRD disenrolled while 19.7% (95% CI: 19.6, 19.9) switched plans within MA compared to a disenrollment rate of 4.2% (95% CI: 4.2, 4.2) and switching rate of 22.8% (95% CI: 22.9, 22.8) for persons without ADRD.
Why it matters
Among non-dually eligible Medicare Advantage beneficiaries, those with Alzheimer disease and related dementias disenrolled at higher rates (9.0%) than those without (4.2%). This may indicate that their care needs are not being met in the program.
-
Microglia are the cells that comprise the innate immune system in the brain.
Why it matters
This review describes how microglia, the brain's immune cells, are now understood to be important in Alzheimer's disease rather than just bystanders. It does not report any treatment, cure, or prevention tested in people.
-
Alzheimer disease is the most common cause of dementia and the fifth leading cause of death in adults older than 65 years.
Why it matters
This paper describes the large and growing financial cost of Alzheimer's disease care, much of it from skilled nursing, home health, and hospice services, with indirect costs likely underestimated. It suggests that managed care organizations could use strategies focused on early diagnosis and treatment to improve outcomes and lower costs.
-
Alzheimer's disease (AD) is the most common cause of dementia in the elderly.
Why it matters
This review says there are currently no effective treatments to treat or slow Alzheimer's disease, and many amyloid-focused therapies have failed or been halted. It describes compounds targeting oxidative stress, redox metals, and neuronal death as still under preclinical or clinical evaluation, not proven treatments.
-
Biomarkers for dementia of Alzheimer's type (DAT) are sought to facilitate accurate prediction of the disease onset, ideally predating the onset of cognitive deterioration.
Why it matters
This study developed a machine-learning score from structural MRI that distinguished stable from progressive mild cognitive impairment, with accuracy depending on how far away conversion was. It is a diagnostic prediction tool and does not test any treatment, cure, or prevention for Alzheimer's disease.
-
Peroxisome proliferator activated receptor alpha (PPAR-α) belongs to the family of ligand-regulated nuclear receptors (PPARs).
Why it matters
This review describes PPAR-alpha as a brain receptor involved in oxidative stress, energy metabolism and inflammation, and proposes it as a possible drug target. It is a review of a target, not a tested treatment or cure.
-
Alzheimer's disease is the most common form of dementia and is a serious health problem.
Why it matters
This study used machine learning on MRI scans from 485 people and found that hippocampus volume can help distinguish Alzheimer's disease, mild cognitive impairment, and cognitively normal people from each other. It is about improving computer-aided diagnosis, not about treating, curing or preventing Alzheimer's disease.
-
Alzheimer disease (AD) is a devastating disease and a global health problem, and current treatments are only symptomatic.
Why it matters
This study looked for changes in protein glycosylation in cerebrospinal fluid and found they correlated with total tau and phosphorylated tau in people with subjective cognitive impairment. It is early biomarker research and does not test any treatment, cure, or prevention.
-
Alzheimer's disease is the leading cause of dementia.
Why it matters
This review states that no disease-modifying agents capable of reversing the initial pathological changes of Alzheimer's disease are currently available. It argues that it may be possible to prevent or delay dementia in a proportion of the population by modifying exposure to common risk factors, and that early diagnosis is still valuable so individuals and carers can plan and access treatments that help manage symptoms.
-
The progressive decrement of neuropsychological performance is associated with HVL long before the emergence of clinically overt symptoms.
Why it matters
In cognitively intact elderly people, declining neuropsychological performance was linked to loss of hippocampal volume over 4.5 years, with no significant interaction found between amyloid positivity and the APOE-ε4 allele. This is about understanding markers of early change, not about treating, curing, or preventing Alzheimer's.
-
Although clinical routine focuses on dichotomous and visual interpretation of amyloid PET, regional image assessment in research settings may yield additional opportunities.
Why it matters
This review summarizes research on regional patterns of amyloid deposition and models for staging amyloid pathology using PET. It discusses earlier identification and staging for research and trials, not a treatment, cure or prevention of Alzheimer's disease.
-
This study provides evidence to support that high Lp(a) concentrations was causally associated with an increased risk of large artery stroke but a decreased risk of small vessel stroke and Alzheimer disease.
Why it matters
This genetic analysis found that higher genetically predicted lipoprotein(a) levels were associated with increased risk of large artery stroke and with Alzheimer disease. It examines a possible causal risk factor but does not test or show any treatment or prevention.
-
Levels of amyloid-β (Aβ) and tau peptides in brain have been associated with Alzheimer disease (AD).
Why it matters
This small study of 22 people with amnestic mild cognitive impairment found that blood levels of Aβ42 and total tau predicted cognitive decline. It is an early observational study with a small sample and does not test any treatment or cure.
-
Alzheimer's disease (AD), a primary cause of dementia in the aging population, is characterized by extracellular amyloid-beta peptides aggregation, intracellular deposits of hyperphosphorylated tau, neurodegeneration and glial activation in the brain.
Why it matters
The lack of early diagnostic criteria is commonly thought to contribute to the failure of Alzheimer's drug therapy and clinical trials, so new biomarkers measurable before symptoms are needed. Evidence from human samples and mouse models suggests protein aggregates and other pathological features may be detectable in the retina, which could allow non-invasive rapid detection.
-
Alzheimer's disease (AD) remains a clinical diagnosis but biomarkers from cerebrospinal fluid (CSF) and more lately amyloid imaging with positron emission tomography (PET), are important to support a diagnosis of AD.
Why it matters
In 64 memory clinic patients, this study compared amyloid PET imaging with cerebrospinal fluid biomarkers and evaluated how well amyloid PET predicted diagnosis. It is a diagnostic study and does not address treating, curing or preventing Alzheimer's disease.
-
47/100
One of the largest unmet medical needs is a disease-modifying treatment for Alzheimer's disease (AD).
Why it matters
This review examines microglial inflammation and phagocytosis, including NLRP3, the complement system and TREM2, as potential therapeutic targets for Alzheimer's disease. It identifies targets for future drug development but reports no effective disease-modifying treatment.
-
Computerized clinical decision support systems can help to provide objective, standardized, and timely dementia diagnosis.
Why it matters
A computerized decision support system using machine learning found that cognitive and functional assessments had high predictive power for Alzheimer's disease severity, with the best support vector machine performance using four cognitive and functional test scores reaching 83.0% multi-class classification accuracy. This is a diagnostic tool and does not test treating, curing or preventing Alzheimer's disease.
-
Alzheimer's disease (AD) is the most common form of dementia and it is characterized by the deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain.
Why it matters
This review describes links between cholesterol metabolism and Alzheimer's disease, noting that cholesterol-lowering therapies have shown mixed results on cognitive performance in patients. It suggests that brain cholesterol metabolism and oxysterols may be potential targets for treatment, but no treatment is tested here.
-
Alzheimer's disease (AD) is the leading cause of dementia worldwide.
Why it matters
This review describes APOE epsilon4 as the major genetic risk factor for late-onset Alzheimer's disease and discusses emerging evidence that APOE may interact with TREM2 in microglia. It is a summary of current understanding and does not report a treatment, cure, or prevention.
-
Alzheimer's disease (AD) is an irreversible, devastating neurodegenerative brain disorder characterized by the loss of neurons and subsequent cognitive decline.
Why it matters
This study identified GPNMB as an Alzheimer's-related factor found in a subset of activated microglia in transgenic mice and in people with sporadic Alzheimer's. It describes a possible marker and does not report a treatment, cure or prevention.
-
The cause of Parkinson's disease (PD) remains unknown in most patients.
Why it matters
This review summarizes genetic, clinical, and neuropathological findings related to 27 genes reported in the literature since 1997 that are associated with Parkinson's disease. It notes that the GBA gene is a major PD risk factor often associated with dementia, and that clinical and neuropathological variability among genes is great.
-
Although sarcopenia is closely linked to dementia, particularly Alzheimer disease (AD), there are few studies examining the prevalence and associated factors of sarcopenia in subjects with AD.
Why it matters
This study investigated the prevalence of sarcopenia and differences in muscle function and gait speed at various stages of Alzheimer's disease in 285 elderly outpatients. It is about muscle function and does not test any treatment, so it says nothing about curing or preventing Alzheimer's disease.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Low cardiac index is associated with incident dementia and Alzheimer disease: the Framingham Heart Study
- Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review
- Detection of Alzheimer and mild cognitive impairment patients by Poincare and Entropy methods based on electroencephalography signals
- Early Behavioral and Cognitive Changes in Patients With Pathologically Confirmed Alzheimer Disease, Lewy Body Dementia, and Mixed Dementia
- Predictors of same-admission cholecystectomy in mild, acute, biliary pancreatitis
- Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
- Neurophysiological Markers of Alzheimer's Disease: Quantitative EEG Approach
- Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report
- Ancestry-specific effects of APOE on Alzheimer Disease Endophenotypes
- Amyloid of neurofibrillary tangles of Guamanian parkinsonism-dementia and Alzheimer disease share identical amino acid sequence